aTyr Pharma Inc expected to post a loss of 22 cents a share - Earnings Preview

aTyr Pharma

06/11/2024 13:54

* aTyr Pharma Inc  ATYR.OQ   ATYR.O  is expected to show a
fall in
quarterly revenue when it reports  results on November 7
(estimated) for the period ending January 1 0001
    * The San Diego California-based  company is expected to
report a
95.3% decrease in revenue to $16.67 thousand from $353 thousand
a year ago, according to the mean estimate from 6 analysts,
based on LSEG data.
    * ​LSEG's mean analyst estimate for aTyr Pharma Inc is for a
loss
of 22 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for aTyr Pharma
Inc
is $19.50​, above​ its last closing price of $3.15. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jun. 30 2024  -0.24       -0.24      -0.23     Beat    3.4
 Mar. 31 2024  -0.25       -0.24      -0.23     Beat    2.5
 Dec. 31 2023              -0.24      -0.25     Missed  -5​
 Jan. 1 0001   -0.22       -0.23      -0.20     Beat    11.5
 ​​Jan.        -0.28       -0.28      -0.22     Beat    21
 1 0001                                                 
 Mar. 31 2023  -0.40       -0.40      -0.29     Beat    27.2​
 Jan. 1 0001   -0.48       -0.48      -0.26     Beat    45.8
 Jan. 1 0001   -0.45       -0.46      -0.46     Met     0.4
 This summary was machine generated November 6 at 13:53 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)